Hiding in Plain Sight-Could a Common Molecular Mechanism Define Neurodegenerative Diseases ?

Many neurodegenerative pathologies such as Alzheimer’s (AD), Parkinson’s (PD), Huntington’s (HD), Creutzfeldt Jakob diseases (CJD) etc. are characterized by severe changes in synaptic functions and eventual neuronal death in the brain. Besides this pathological commonality, all these diseases possess a biochemical commonality in which the respective proteins aggregate to form amyloids that are known to be responsible for neuronal cell death. Amyloid formation involves the conversion of proteins from their native monomeric states (intrinsically disordered or globular) to well-organized, fibrillar aggregates in a nucleation-dependent manner. Although amyloid-diseases differ in their functional and some pathological aspects, all amyloidogenic proteins, irrespective of their native structure form a cross β-sheet structural core upon aggregation. Interestingly, the unique ability of this conformation to accommodate tightly packed interactions is reflected in its remarkable conservation among all amyloids, despite significant sequence diversity.

[1]  C. Olanow,et al.  Parkinson's Disease and Alpha Synuclein: Is Parkinson's Disease a Prion‐Like Disorder? , 2013, Movement disorders : official journal of the Movement Disorder Society.

[2]  N. Cairns,et al.  Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia. , 2012, Archives of neurology.

[3]  Stephen J. DeArmond,et al.  Purified and synthetic Alzheimer’s amyloid beta (Aβ) prions , 2012, Proceedings of the National Academy of Sciences.

[4]  K. Jellinger,et al.  Interaction between pathogenic proteins in neurodegenerative disorders , 2012, Journal of cellular and molecular medicine.

[5]  M. Jucker,et al.  Pathogenic protein seeding in alzheimer disease and other neurodegenerative disorders , 2011, Annals of neurology.

[6]  J. Trojanowski,et al.  Synergistic Interactions between Aβ, Tau, and α-Synuclein: Acceleration of Neuropathology and Cognitive Decline , 2010, The Journal of Neuroscience.

[7]  S. Strittmatter,et al.  β-amyloid oligomers and cellular prion protein in Alzheimer’s disease , 2010, Journal of Molecular Medicine.

[8]  P. Westermark,et al.  Fibrils from Designed Non-Amyloid-Related Synthetic Peptides Induce AA-Amyloidosis during Inflammation in an Animal Model , 2009, PloS one.

[9]  John W. Gilbert,et al.  Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers , 2009, Nature.

[10]  H. Laude,et al.  Prion agent diversity and species barrier. , 2008, Veterinary research.

[11]  N. Makarava,et al.  Highly Promiscuous Nature of Prion Polymerization* , 2007, Journal of Biological Chemistry.

[12]  Jonathan S. Weissman,et al.  The physical basis of how prion conformations determine strain phenotypes , 2006, Nature.

[13]  J. Weissman,et al.  Mechanism of Cross-Species Prion Transmission An Infectious Conformation Compatible withTwo Highly Divergent Yeast Prion Proteins , 2005, Cell.

[14]  W. Surewicz,et al.  Molecular basis of barriers for interspecies transmissibility of mammalian prions. , 2004, Molecular cell.

[15]  J. Griffith,et al.  Self-replication and scrapie. , 1967, Nature.